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a  b  s  t  r  a  c  t
The  aim  of the  study  was to  investigate  the  protective  effect  of  isoniazid–curcumin  con-
jugate (INH–CRM)  in INH-induced  hepatic  injury  by  biochemical  analysis  and  histology
examination  of liver  in Wistar  rats.  The  biochemical  analysis  included  determination  of
the levels  of plasma  cholesterol,  triglycerides  (TG),  albumin  content,  and  lipid  peroxidation
(MDA).  INH–CRM  administration  resulted  in a signiﬁcant  decrease  in plasma  cholesterol,
TG,  and  MDA  levels  in the  liver  tissue  homogenate  with  an elevation  in albumin  level  indi-
cating its hepatoprotective  activity.  Histology  of  the  liver  further  conﬁrmed  the  reduction
in hepatic  injury.  The  hepatoprotective  with INH–CRM  can  be attributed  to  the  antioxidant
activity  of curcumin.  The  conjugate  probably  stabilizes  the  curcumin  molecule,  preventing
its  presystemic  metabolism  thereby  enhancing  its bioavailability  and  therefore,  its  hepato-
protective  activity.  Thus,  the  novel  INH–CRM  has the potential  to alleviate  INH-induced
liver  toxicity  in antitubercular  treatment.riethylamine (PubChem CID: 8471)
-Dimethylaminopyridine (PubChem CID:
4284)
uccinic Acid (PubChem CID: 1110)
uccinic Anhydride (PubChem CID: 7922)
itric Acid (PubChem CID: 31348)
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. IntroductionTuberculosis (TB) is a contagious disease which is a
ajor  challenge to public health. After AIDS, TB is the sec-
nd  most infectious disease [1,2] caused by the intracellular
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http://creativecommons.org/licenses/by-nc-nd/3.0/).parasite Mycobacterium tuberculosis (MTB). The standard
treatment consists of ﬁrst-line anti-TB drugs (ATDs) viz.,
rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and
ethambutol (ETH). The administration of INH, one of the
mainstream antitubercular drug results in many metabolic
and  morphological aberrations in the liver, which is its
main  detoxifying site. INH after metabolism in the liver
produces hydrazine metabolites (nitrogen-centered free
radicals).  These radicals generate highly reactive oxygen
is is an open access article under the CC BY-NC-ND license
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species, which act as stimulator of lipid peroxidation result-
ing  in cell death and hepatic necrosis [3].
Phenolic substances have received much attention due
to  their biological activities and antioxidant properties [4].
Curcumin  (CRM), 1,7-Bis(4-hydroxy-3-methoyphenyl)-
1,6-heptadiene-3,5-dione, is a typical representative that
exhibits  powerful antioxidant effects in biological sys-
tems,  including free radical scavenging and metal ion
sequestering [5–7]. CRM has exhibited antioxidant, anti-
inﬂammatory, antimicrobial, anticarcinogenic, and hep-
atoprotective activities [8]. However, CRM exhibits poor
oral  bioavailability which is associated with its poor solu-
bility  and extensive presystemic and systemic metabolism
[9]. Among the methods adopted to enhance its oral
bioavailability, conjugation has been widely explored. Con-
jugation  with water-soluble moieties has been reported
to  increase CRM solubility and decrease the extent of its
presystemic metabolism [10].
It is used in the food and pharmaceutical industry as
a  stabilizer, natural colorant, and substitute for artiﬁcial
colorants in cheese, soup, pickle, etc.
Various attempts have been made to overcome the
antitubercular drug induced toxicity. They include con-
jugation with peptide, polyethylene-glycol and gelatin
[11–13]. The aim of this study was the synthesis of a novel
isoniazid–curcumin conjugate (INH–CRM) for improved
toxicity proﬁle of INH. INH–CRM formation was conﬁrmed
by  mass spectroscopy and NMR. Further, the toxicity of the
conjugate  was compared with INH by biochemical analy-
sis  and histopathology. INH–CRM demonstrated signiﬁcant
improvement in hepatoprotective activity indicating its
potential  in tubercular therapy.
2. Materials and methods
2.1.  Materials
INH was purchased from All Well Pharma, Chandi-
garh, India. 1-Ethyl-3-(3-dimethylaminopropyl) carbodi-
imide  hydrochloride (EDAC) was bought from HiMedia
Laboratories Pvt. Ltd. Mumbai, India. CRM (95%), Dicy-
clohexylcarbodiimide (DCC), Triethylamine (TEA) and
4-(dimethylamino) pyridine (DMAP), succinic acid, and
succinic  anhydride were bought from Sigma-Aldrich (Mis-
souri,  USA). Citric acid was purchased from HiMedia
Laboratories Pvt. Ltd., Mumbai, India. All other solvents
were of analytical grade.
2.2.  Synthesis of isoniazid–curcumin conjugate
An intermediate was synthesized by treating INH
(10 mMol) with aqueous glyoxylic acid monohydrate
(10 mMol) solution. The intermediate was mixed with CRM
(equimolar amounts) in DCM and stirred constantly for
thirty  minutes at room temperature in a nitrogen atmo-
sphere. Then DMAP was added in the catalytic amount of
8  mol  % followed by EDAC after 15 min. Reaction was con-
tinued  for 12 h to yield INH–CRM.Fig. 1. Experimental design of the animal studies.
2.3. Characterizations of INH–CRM conjugate
2.3.1. NMR
The  NMR  of INH, CRM, intermediate, and INH–CRM was
obtained from Bruker 400 UltraShieldTM (Bruker, Germany)
spectrometer. The data were processed and analyzed with
Topspin  software.
2.3.2.  Mass spectroscopy
To  conﬁrm the formation of INH–CRM conjugate,
samples were dissolved in methanol then ﬁltered and ana-
lyzed  by mass spectroscopy (LCQ, Finnigan, MAT  system
equipped with Xcaliber software).
2.4. In vivo study for hepatoprotective activity
All animal experiment protocols were approved by
the  Institutional Animal Ethics Committee (IAEC No.
108/1999/CPCSEA) and studies were performed in accor-
dance  with the CPCSEA (Committee for Purpose of Control
and  Supervision of Experimentation on Animals) guide-
lines.  Wistar rats (180–200 g) were procured from the
Central Animal Facility (CAF) of the institute. All the ani-
mals  were maintained under controlled environmental
conditions at room temperature (22 ± 2 ◦C) with 50 ± 10%
RH.  Animals were acclimatized for 1 week prior to experi-
mentation.







tFig. 2. NMR sp
.4.1. Experimental design
The study was conducted for 21 days. Animals were
ivided into nine groups (Fig. 1). There is considerable
ariation in INH and CRM doses for studies. Dose selec-
ion  was done purely on the basis of reports available in
he  literature for INH [14,15] and CRM [16–20], respec-
ively. Group I formed the negative control. Groups II and
Fig. 3. NMR  spectra o intermediate.
III  were administered INH at 150 and 200 mg/kg/day doses,
respectively. Groups IV and V were administered CRM at
405  and 540 mg/kg/day doses, respectively. Groups VI and
VII  were administered INH–CRM at 645 and 860 mg/kg/day
doses. Groups VIII and IX were administered combination
of free INH (150 and 200 mg/kg/day) and CRM (405 and
540  mg/kg/day), respectively. The hepatoprotective effect
f conjugate.
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ol levelsFig. 4. (A) Effect of INH–CRM on plasma TG levels; (B) plasma cholester
values  are expressed as mean ± SEM (n = 4), ***p < 0.001 vs INH-200.
of CRM was compared with the conjugate. Each experimen-
tal  group was containing four animals for the study.
3.  Toxicity proﬁle
3.1.  Biochemical parameters
The  triglyceride and cholesterol levels were measured
with spectrophotometric kits (Accurex Biomedical Pvt.
Ltd.,  Mumbai, Maharashtra, India). Brieﬂy, blood samples
(approximately 0.6 mL)  were collected from the retro-
orbital plexus under light ether anesthesia in heparinized
microcentrifuge tubes. Plasma was separated by centrifu-
gation at 2500 × g for 5 min  and analyzed.
3.2. Measurement of lipid peroxidation
Lipid peroxidation was quantiﬁed by the thiobarbituric
acid reactive substance method, with some modiﬁcations.
The level of malondialdehyde (MDA), the end product of
lipid  peroxidation is measured by this method. In brief,
tissues were collected and homogenized in an ice cold
phosphate buffer (pH 7.4). After centrifugation, the super-
natant  was collected and MDA  levels were measured. Lipid
peroxidation was calculated from the standard curve of 1,
1,  3, 3-tetramethoxy propane (97%) and expressed as nmol
MDA/mg  of protein [21]. at the end of 3 weeks. INH–CRM was given p.o/day during 3 weeks. All
3.3. Determination of protein content
Protein concentration in the tissue homogenate was
determined by utilizing bovine serum albumin (BSA)
(Sigma-Aldrich, USA) as the standard protein.
3.4. Histopathological evaluation
The morphological changes in the hepatic tissue were
assessed by histopathology. Tissue sections were ﬁxed in
10%  formalin solution, dehydrated in increasing concen-
trations of ethanol followed by engrafting in parafﬁn. The
sections  were mounted on glass slides coated with Mayer’s
albumin and dried overnight. They were de-parafﬁnized
with xylene, rehydrated with alcohol, and water mixture.
The  rehydrated sections were stained with hematoxylin
and eosin, mounted with DPX media and viewed under
the  microscope at both high (40×) and low (10× and 20×)
magniﬁcations (Olympus BX51 microscope, Tokyo, Japan)
[22].
3.5.  Statistical analysis
Results  are presented as mean ± standard error of mean
(SEM) for each group. Statistical analysis was performed
using Jandel Sigma Stat (Version 3.5) statistical software.
Signiﬁcance of the difference between two groups was
evaluated using Student’s t-test. For multiple comparisons,
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Iig. 5. (A) Effect of INH–CRM on liver MDA  levels; (B) plasma albumin lev
re  expressed as mean ± SEM (n = 4) ***p < 0.001 vs INH-200.
ne-way analysis of variance (ANOVA) was employed.
hen ANOVA exhibited signiﬁcant difference, post-hoc
nalysis was performed with Tukey’s test. P < 0.05 was  con-
idered  to be statistically signiﬁcant.
. Results
.1. Synthesis of INH–CRM
The  conjugate was composed of 1:1 molar ratio of CRM
nd  INH. The fraction of
CRM  was about 0.728 while INH was 0.272 in the
NH–CRM. Synthesis of INH–CRM was through an inter-
ediate compound which was then reacted with CRM to
btain  INH–CRM.
.2.  Characterization of INH–CRM
.2.1. Nuclear magnetic resonance
NMR spectrum of the intermediate (Fig. 2) exhibits a
haracteristic proton peak at 2.5 ppm indicating the “d”
roton  of the intermediate. INH–CRM (Fig. 3) presented
 chemical shift at 1.53 ppm corresponding to “d” proton,
hich is absent in CRM. In addition, the characteristic peaks
t  8.81, 8.34, and 8.19 ppm in the conjugate indicate the
resence of “a,” “b,” and “c” protons, respectively, conﬁrms
NH–CRM formation.e end of 3 weeks. INH–CRM was given p.o/day during 3 weeks. All values
4.2.2.  Mass spectra
The  MS  spectra of INH–CRM revealed the formation of
INH–CRM exhibiting m/z  peak at 545.11 while interme-
diate’s peak was  at m/z  195 (Data not presented). Hence,
results of NMR  and mass spectra support each other in
conﬁrming INH–CRM formation.
4.3. Animal studies
4.3.1.  Biochemical assays
Biochemical  tests indicating hepatocellular integrity
were analyzed. Body weights increased in all the groups at
the  end of the study with no signiﬁcant difference between
the  groups. Mortality rate (25%) was  observed during entire
study  protocol from INH 200 mg/kg group. Similar results
are  reported in earlier studies [23]. INH administration
resulted in a signiﬁcant elevation in plasma triglycerides,
cholesterol, and malondialdehyde (MDA) levels indicat-
ing  its impact on integrity of hepatocytes with signiﬁcant
decrease in albumin levels [5]. The decrease in albumin
level indicates the effect of INH on liver function.
In the INH–CRM group, TG level decreased signiﬁcantly
(p < 0.001) in comparison to the group treated with INH
(dose  of 200 mg/kg/day) thus demonstrating its hepatopro-
tective activity. TG level decrease, to a lesser extent, in the
group  treated with combination of INH and CRM and in
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of groupFig. 6. Histological section of control group (A); histological section 
the CRM group. This decrease in plasma TG level can be
attributed to the antioxidant effect of CRM (Fig. 4A).
Santhosh et al. [24] reported an increase in choles-
terol level due to the devastating effect of hepatotoxic
agents which disrupt membrane ﬂuidity thereby affecting
its  functions. In agreement with this study, we observed
that altered levels of plasma cholesterol in INH-treated rats
in  comparison to the control and INH–CRM-treated groups.
Plasma cholesterol level was signiﬁcantly (p < 0.001)
reduced in INH–CRM-treated group in comparison to INH
(200  mg/kg/day) group demonstrating hepato-protection
of INH–CRM. In the INH and CRM combination group, the
level  of plasma cholesterol was less than in INH group.
Thus, plasma cholesterol studies revealed that INH–CRM
offered a signiﬁcant protection against INH-induced alter-
ation  in the plasma cholesterol level. This observation can
be  attributed to CRM antioxidant properties (Fig. 4B).
MDA  is a free radical which increases in hepatotoxic
conditions. Its concentration is an index of lipid peroxi-
dation. Some studies have also reported the thiobarbituric
acid-reactive substances (TBARS) levels as an index of MDA
[25–28].  Fig. 5A indicates signiﬁcant (p < 0.001) decrease
in  MDA  levels in the liver tissue homogenate of INH–CRM
treated vs INH-treated group. Although, the group admin-
istered  combination of INH and CRM exhibited low MDA
level  in comparison to free INH, the decrease was  sub-
stantially less than the conjugate group. The decreased
MDA  formations following INH–CRM treatment conﬁrms treated with CRM 405 mg/kg/day (B); and CRM 540 mg/kg/day (C).
the  hepatoprotective and antioxidant properties of CRM,
as  reported in previous studies [18,29,30].
Hepatic damage inﬂuences normal cellular metabolism
[31]. Liver synthesizes albumin and a low serum albumin
level  indicates poor liver function suggesting liver disease
[32].  The level of albumin signiﬁcantly (p < 0.001) (Fig. 5B)
increased in INH–CRM groups more than in case of combi-
nation of INH and CRM or CRM alone, thus conﬁrming its
effectiveness.
Hence,  results of the biochemical evaluations indi-
cate INH–CRM potential in alleviating the drug-induced
hepatotoxicity. The enhanced activity of the conjugate
can be assigned to its effect in reducing the presystemic
metabolism of CRM by steric hindrance [33].
4.3.2. Histopathological evaluation
Rats have been successfully employed as models to
investigate INH-induced hepatotoxicity. In the present
study, INH was orally administered for 21 days to induce
hepatoxicity in the test animals.
Histopathology was undertaken to examine the mor-
phological changes in the hepatic tissue. In the tissue
sections, INH exhibited changes in the normal architecture
of  the parenchyma cells with swelled hepatocytes and loss
of  the cell boundaries. Liver histology of the control group
(Fig.  6A) and the groups treated with 405 and 540 mg/kg
of  CRM presented the normal morphology (Fig. 6B and
C).  Each cell displayed well-deﬁned boundaries, round
C. Singh et al. / Toxicology Reports 1 (2014) 885–893 891





















Hepatotoxicity score of control rats, treated with CRM, INH alone, INH co
treated with CRM and INH–CRM.
Groups Histopathology score
0 1+ 2+ 3+
Control 4
CRM 405 mg/kg 4
CRM 540 mg/kg 4
INH 150 mg/kg 1 3
INH  200 mg/kg* 3
INH  150 + CRM 405 mg/kg 2 2
INH  200 + CRM 540 mg/kg 3 1
INH–CRM  645 mg/kg 3 1
INH–CRM 860 mg/kg 3 1
0, no injury; 1+, mild injury (a few hepatocytes affected); 2+, moderate
injury (necrosis in some hepatocytes); 3+, severe injury (swelled hepato-ig. 7. Histological section of groups treated with INH 150 mg/kg/day (A
D);  conjugate 645 mg/kg/day (E); and conjugate 860 mg/kg/day (F).
esicular, and centrally located nucleus. Few binucleated
ells were also seen in CRM treated groups. Thus, the score
as  counted as 0 for control as well as CRM-treated ani-
als.
Histological and biochemical data correlated, with an
levation in liver function tests with hepatocellular necro-
is  in 150 and 200 mg/kg INH-treated groups (Fig. 7A and
).  This tissue section showed deeply stained nuclei with
atchy  liver and was considered as severely damaged in
he  tissue section of animals administered with high dose.
owever, the damage was moderate in the animals admin-
stered  with low dose and hence, histopathology score
as  taken as “2” and “3,” for low and high dose, respec-
ively. Moderate histopathological necrosis was observed
n  INH + CRM treated groups as displayed in the Fig. 7C
nd  D. Therefore, histopathology score was considered
s “2.” INH–CRM administration signiﬁcantly (p < 0.001)
mproved the tissue fabric (Fig. 7E and F) in comparison to
NH  + CRM. The majority of the hepatic lobules preservedcytes, patchy liver with necrosis). Values are the number of animals with
the  indicated score. *One animal died during study.
ogy Repo892 C. Singh et al. / Toxicol
the normal architecture with limited hepatic change
and hence histopathology score was expressed as “0.”
Histopathology score data are compiled in the Table 1. The
primary  reason for the protective effect of INH–CRM is the
antioxidant activity of curcumin due to the quenching of
free  radical and reactive oxygen species [17].To the best of
our  knowledge, the conjugation of INH and CRM and study
of  its effect on INH-induced hepatotoxicity has not been
reported in the literature. In the present study, INH–CRM
at  two doses prevented histological changes associated
with isoniazid toxicity. Histopathology results agree with
the  biochemical ﬁndings. Thus, it can be concluded that
INH–CRM is efﬁcacious for management of INH-induced
hepatotoxicity.
5. Discussion
INH is metabolized by acetylation induced by the
hepatic enzyme N-acetyl transferase. INH is acetylated to
acetyl  isoniazid, which is hydrolyzed into acetyl hydrazine
and  isonicotinic acid. Polymorphism in NAT-2 has been
identiﬁed that divides the human population to ‘slow’
and  ‘rapid’ acetylators. Slow acetylators shunt INH into a
secondary  metabolic pathway producing hydrazine. Both
hydrazine  and acetyl hydrazine are toxic metabolites that
generate  free radicals [3]. This results in reduced lev-
els  of glutathione, glutathione-S transferase, catalase and
superoxide dismutase. Glutathione represents the non-
enzymatic scavengers while glutathione-S transferase,
catalase and superoxide dismutase, the enzymatic systems
are  involved in the detoxiﬁcation free radicals.
In the present study, INH caused liver injury in rats
at  the dose levels investigated. The animals treated with
the  larger INH dose, developed signiﬁcant hepatic dam-
age  with a substantial increase in serum parameter’s
concentrations. Treatment with INH–CRM resulted in a
considerable alleviation of the toxicity, indicated by the
alteration of cholesterol, albumin and lipid peroxidation
levels. INH–CRM is thus effective in tuberculosis therapy.
The effectiveness can be attributed to the antioxidant activ-
ity  of curcumin.
Hepatic cells are involved in variety of metabolic
activities. The transport function of the hepatocytes is
particularly disturbed, after liver damage, as a result of
deterioration of the plasma membrane. This leads to the
loss  of functional integrity of cell membranes in the liver
[34].  Most of the hepatotoxic chemicals damage the liver,
principally by inducing lipid peroxidation directly or indi-
rectly  In higher animals, peroxy radicals mediate lipid
peroxidation thereby destroying cell membrane integrity,
leading to liver injury, atherosclerosis, and kidney dam-
age  [35]. In this study work, INH–CRM was effective in
reducing the level of malondialdehyde (MDA), a major
reactive aldehyde, which appears during the peroxida-
tion of polyunsaturated fatty acid present in the biological
membrane [36]. The liver of INH-treated rats exhibits mas-
sive  liver deterioration. The hepatic MDA  level is employed
as  a biochemical indicator of liver tissue destruction [21].
The  biochemical results were supplemented with liver
histopathology. The liver of INH-treated group exhibits
massive liver deterioration. INH–CRM administrationrts 1 (2014) 885–893
signiﬁcantly improved the tissue fabric. The histological
observation is further supported by serum levels of TG,
albumin, cholesterol and MDA. However, studies on the
biochemical mechanisms responsible for the hepatopro-
tective effect of INH–CRM would be necessary
6. Conclusions
INH–CRM was successfully synthesized by employing
glyoxylic acid and EDAC as linker and coupling agent,
respectively. DMAP was used as the catalyst. The study
of  the biochemical parameters has demonstrated that the
conjugate  possesses signiﬁcant hepatoprotective activity
in  comparison to the combination of INH and CRM. Levels
of  TG, cholesterol, and MDA  were considerably signiﬁcantly
reduced after INH–CRM treatment, including an appre-
ciable increase in plasma albumin level. Histopathological
evaluations further conﬁrm the effectiveness of INH–CRM
treatment in reducing liver necrosis. Hence, based on
biochemical and histopathological evaluation, it can be
concluded that INH–CRM has the potential for optimizing
antitubercular therapy.
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